Morning@Oxford2000 I'm picking there will be some significant News / ASX Announcement regarding SNT 6302 , my own view after listening to Gary is that SNT 6302 may well be spun off into another Company with SNT as the dominant SH.
Dermal / skin applied Topical Creams are low on the Complexity Matrix for commercialisation,,, coupled to Fiona Wood as the Principal Investigator and being the inventor /Developer of Liquid Skin with the amount of data gathered through the successful Phase I and her ongoing trialing IMHO there would be ample data available now to apply for regulatory approval to go to market with SNT 6302..
There is no SOC Standard of Care, there is no incumbent that you have to compete with ,, the market space is wide open and SNT really have First Mover Advantage here... imagine SNT 6302 being utilised on fresh surgical scars .. plus there was a single line that gary stated "we have been in touch or had interest shown by the Cosmetic Surgery industry" or similar to that effect,,
This month we definitely know there is additional Phase II Interim Data from the SNT 5505 Trial....
and that should be utilised as a Catalyst by SNT to push the Company forward front and centre to increase market wide interest in the Company and a subsequent increase in demand for shares,,,which leads to my Favourite outcome ,, increased SH Value $$$$$
Add to My Watchlist
What is My Watchlist?
